Cargando…

RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I study

Detalles Bibliográficos
Autores principales:	Watts, Gerald F., Chan, Dick C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679969/ https://www.ncbi.nlm.nih.gov/pubmed/38009403 http://dx.doi.org/10.1002/ctm2.1484

Ejemplares similares

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
por: Watts, Gerald F., et al.
Publicado: (2023)

The iPSC Awakens ANGPTL3 in Tangier Disease
por: Lee, Man K.S., et al.
Publicado: (2017)

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
por: Gaudet, Daniel, et al.
Publicado: (2020)

ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
por: Chi, Xun, et al.
Publicado: (2017)

siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy
por: Hu, Bo, et al.
Publicado: (2023)

The role of ANGPTL3 in controlling lipoprotein metabolism
por: Tikka, Anna, et al.
Publicado: (2016)

Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study
por: Chan, Sammy Y, et al.
Publicado: (2008)

Novel Insights Into the Regulation of Postprandial Lipemia by Glucagon-Like Peptides: Significance for Diabetes
por: Watts, Gerald F., et al.
Publicado: (2013)

Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care
por: Loh, Wann Jia, et al.
Publicado: (2022)

ANGPTL4/8 promotes plasmin-mediated cleavage of LPL inhibitors
por: Kersten, Sander
Publicado: (2023)

Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome
por: Chan, Dick C., et al.
Publicado: (2009)

GALNT2 rs4846914 SNP Is Associated with Obesity, Atherogenic Lipid Traits, and ANGPTL3 Plasma Level
por: Qaddoumi, Mohammad, et al.
Publicado: (2022)

Anti-atherogenic effects of fibrates in type 2 diabetes
por: Barter, Philip
Publicado: (2001)

Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile
por: Corey, Kathleen E, et al.
Publicado: (2014)

VLDL receptor gene therapy for reducing atherogenic lipoproteins
por: Krauss, Ronald M., et al.
Publicado: (2023)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Window of Opportunity: Targeting ANGPTL4 Improves Triglyceride Levels in Maternal Obesity During Pregnancy
por: Alejandro, Emilyn U., et al.
Publicado: (2020)

Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
por: Chen, Pei-Yi, et al.
Publicado: (2021)

Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects
por: Cartolano, Flávia De C., et al.
Publicado: (2017)

The Impact of RNA Interference in Tick Research
por: de la Fuente, José, et al.
Publicado: (2022)

Angiopoietin-like 4 (Angptl4): A glucocorticoid-dependent gatekeeper of fatty acid flux during fasting
por: Koliwad, Suneil K., et al.
Publicado: (2012)

ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding
por: Lund Winther, Anne-Marie, et al.
Publicado: (2021)

High Density Lipoprotein Particle Size in Children: Relation to Atherogenic Dyslipidemia
por: Numata, Michio
Publicado: (2004)

Is Lipid Accumulation Product Associated with an Atherogenic Lipoprotein Profile in Brazilian Subjects?
por: Cartolano, Flavia De Conti, et al.
Publicado: (2018)

The Ratio of Unesterified/esterified Cholesterol is the Major Determinant of Atherogenicity of Lipoprotein Fractions
por: Bagheri, Babak, et al.
Publicado: (2018)

The LipoGlo reporter system for sensitive and specific monitoring of atherogenic lipoproteins
por: Thierer, James H., et al.
Publicado: (2019)

Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients
por: Peela, Jagannadha R, et al.
Publicado: (2018)

Long-term fasting improves lipoprotein-associated atherogenic risk in humans
por: Grundler, Franziska, et al.
Publicado: (2021)

The Effect of Untraditional Lipid Parameters in the Development of Coronary Artery Disease: Atherogenic Index of Plasma, Atherogenic Coefficient and Lipoprotein Combined Index
por: Çelik, Ersin, et al.
Publicado: (2021)

RNA interference: a multifaceted innate antiviral defense
por: Kumar, Ajit
Publicado: (2008)

ESF-EMBO Symposium: Antiviral Applications of RNA Interference
por: ter Brake, Olivier, et al.
Publicado: (2008)

The RNA interference pathway: a new target for autoimmunity
por: Pruijn, Ger JM
Publicado: (2006)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
por: Ying, Qidi, et al.
Publicado: (2021)

Predictive value of atherogenic index of plasma and atherogenic index of plasma combined with low-density lipoprotein cholesterol for the risk of acute myocardial infarction
por: Chen, Min, et al.
Publicado: (2023)

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol
por: Lawler, Patrick R., et al.
Publicado: (2017)

Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study
por: Ikezaki, Hiroaki, et al.
Publicado: (2021)

Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism
por: Yang, Longyan, et al.
Publicado: (2019)

On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety
Publicado: (1995)

Prevalence and Predictors of Atherogenic Serum Lipoprotein Dyslipidemia in Women with Obstructive Sleep Apnea
por: Xia, Yunyan, et al.
Publicado: (2017)

Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action
por: Nagao, Manabu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_td5k6ccmpk78fp6pejqpg35l7u